Treatment-Resistant Hypertension Market: Epidemiology, Therapies, Companies, DelveInsight | Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences

Treatment-Resistant Hypertension therapies, such as Baxdrostat (CIN-107), Lorundrostat (MLS-101), TRYVIO/JERAYGO (aprocitentan), and others, are expected to boost the Treatment-Resistant Hypertension Market in the upcoming years.

DelveInsight has launched a new report on "Treatment-Resistant Hypertension - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Treatment-Resistant Hypertension, historical and forecasted epidemiology as well as the Treatment-Resistant Hypertension market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Treatment-Resistant Hypertension market report @ https://www.delveinsight.com/report-store/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Treatment-Resistant Hypertension Market Report:
In March 2024, the U.S. Food and Drug Administration (FDA) approved TryvioTM (aprocitentan), marking a significant advancement in the treatment of resistant hypertension. This condition affects approximately 20% of individuals with high blood pressure, characterized by blood pressure that remains elevated despite the use of multiple antihypertensive medications.
In 2024, the United States held the largest market share for Treatment-Resistant Hypertension (TRH) among the seven major markets (7MM), with an estimated value of around USD 6,210 million. This figure is projected to grow further by 2034. Among the various treatment options within the 7MM, Calcium Channel Blockers (CCBs) represented the highest market value in 2024, generating approximately USD 2,110 million.
Idorsia Pharmaceuticals is actively pursuing global partnerships to broaden its market reach. However, the company recently experienced a setback when a planned exclusivity deal for the worldwide rights to aprocitentan fell through. Nevertheless, Idorsia has restarted talks with other prospective partners.
Key competitors in this field include AstraZeneca (baxdrostat), Mineralys Therapeutics (lorundrostat), E-Star BioTech (MANP), Ionis Pharmaceuticals and Kardiga (tonlamarsen), Regeneron Pharmaceuticals (REGN5381), and Alnylam Pharmaceuticals in collaboration with Roche (zilebesiran).
Several TRH drugs in development feature diverse mechanisms of action, such as aldosterone synthase inhibitors (baxdrostat, lorundrostat), Guanylyl Cyclase A (GC-A) receptor activators (MANP), Natriuretic Peptide Receptor 1 (NPR1) agonists (REGN5381), angiotensinogen expression inhibitors (zilebesiran), and agents targeting angiotensinogen (tonlamarsen). If successful, these candidates could expand treatment options and increase competition within the market.
In 2024, there were about 7,365,300 diagnosed cases of treatment-resistant hypertension (TRH) in the United States, with numbers expected to rise throughout the forecast period from 2025 to 2034. In Japan, females accounted for a slightly higher proportion of diagnosed cases-approximately 55% in 2024-with this percentage projected to grow by 2034.
Key Treatment-Resistant Hypertension companies such as Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others are evaluating new drugs for Treatment-Resistant Hypertension to improve the treatment landscape.
Promising Treatment-Resistant Hypertension therapies include Baxdrostat (CIN-107), Lorundrostat (MLS-101), TRYVIO/JERAYGO (aprocitentan), and others.

Treatment-Resistant Hypertension Overview

Resistant hypertension (RHT) is defined as blood pressure that remains above 130/80 mmHg despite the use of three or four different antihypertensive medications, including a thiazide diuretic, all at the highest tolerated doses. It also includes cases where blood pressure is controlled but requires four or more medications. Patients with uncontrolled high blood pressure despite adequate treatment may have RHT or refractory hypertension. Those controlled on multiple drugs might still benefit from specialist evaluation to rule out pseudo-resistance or secondary causes and to optimize treatment, avoiding overtreatment.

Blood pressure regulation involves complex interactions between systems like the Renin-Angiotensin-Aldosterone System (RAAS), Sympathetic Nervous System (SNS), endothelin system, natriuretic peptides, vascular function, and the immune system. Hypertension can result from dysfunction in any of these systems, influenced by genetics, lifestyle factors (e.g., high salt intake, low potassium, sleep apnea, alcohol use, inactivity, stress), and aging.

Often symptomless, hypertension requires regular monitoring. Extremely high blood pressure (≥180/120 mmHg) may cause symptoms such as headaches, chest pain, dizziness, vision problems, and irregular heartbeat. If untreated, it significantly increases the risk of serious complications like heart disease, stroke, and kidney damage.

Treatment-Resistant Hypertension Market Outlook

Resistant hypertension leads to damage in blood vessels, increasing the risk of cardiovascular events. Older adults (aged 65 and above), individuals with obesity, and those with conditions like diabetes, chronic kidney disease (CKD), or left ventricular hypertrophy often struggle more with controlling their blood pressure. Compared to patients with controlled blood pressure, those with resistant hypertension have higher incidences of diabetes (48% vs. 30%), CKD (45% vs. 24%), ischemic heart disease (41% vs. 22%), and stroke (16% vs. 9%).

Treatment of resistant hypertension involves lifestyle modifications-such as maintaining a healthy weight through regular exercise and a balanced diet, reducing salt intake, limiting alcohol consumption, and quitting smoking-alongside medication and, if necessary, interventional procedures. Medication typically includes a combination of a renin-angiotensin system blocker, a long-acting calcium channel blocker, and a diuretic at the highest tolerable doses, preferably combined into a single pill. Spironolactone is currently the recommended fourth-line drug, while alternatives include alpha-blockers, beta-blockers, centrally acting sympatholytics, or vasodilators. If these measures fail to control blood pressure, interventional techniques like renal denervation or new therapeutic drugs (when available) may be considered.

Lifestyle changes are critical in managing resistant hypertension. A recent meta-analysis found lifestyle interventions to be the most effective non-pharmacological strategy, reducing systolic blood pressure by an average of 7.26 mmHg. Diets such as the DASH diet-rich in whole grains, fruits, vegetables, and low-fat dairy and low in saturated fats and sugars-as well as the Mediterranean diet, have shown beneficial effects. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist (nsMRA), offers a promising alternative by blocking aldosterone's effects regardless of its presence. Although spironolactone is the preferred treatment, its anti-androgenic side effects limit its use in men, and options are scarce for patients who are intolerant or develop hyperkalemia.

Discover how the Treatment-Resistant Hypertension market is rising in the coming years @ https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Treatment-Resistant Hypertension Marketed Drug
TRYVIO/JERAYGO (aprocitentan): Idorsia Pharmaceutical
Treatment-Resistant Hypertension Emerging Drugs
Baxdrostat (CIN-107): AstraZeneca
Lorundrostat (MLS-101): Mineralys Therapeutics

Scope of the Treatment-Resistant Hypertension Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Treatment-Resistant Hypertension Companies: Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others
Key Treatment-Resistant Hypertension Therapies: Baxdrostat (CIN-107), Lorundrostat (MLS-101), TRYVIO/JERAYGO (aprocitentan), and others
Treatment-Resistant Hypertension Therapeutic Assessment: Treatment-Resistant Hypertension current marketed and Treatment-Resistant Hypertension emerging therapies
Treatment-Resistant Hypertension Market Dynamics: Treatment-Resistant Hypertension market drivers and Treatment-Resistant Hypertension market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Treatment-Resistant Hypertension Unmet Needs, KOL's views, Analyst's views, Treatment-Resistant Hypertension Market Access and Reimbursement

To know what's more in our Treatment-Resistant Hypertension report, visit https://www.delveinsight.com/report-store/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Treatment-Resistant Hypertension Market Report:
Treatment-Resistant Hypertension market report covers a descriptive overview and comprehensive insight of the Treatment-Resistant Hypertension Epidemiology and Treatment-Resistant Hypertension market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Treatment-Resistant Hypertension market report provides insights into the current and emerging therapies.
The Treatment-Resistant Hypertension market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Treatment-Resistant Hypertension market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Treatment-Resistant Hypertension market.

Got queries? Click here to know more about the Treatment-Resistant Hypertension market Landscape https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Treatment-Resistant Hypertension Patient Share (%) Overview at a Glance
5. Treatment-Resistant Hypertension Market Overview at a Glance
6. Treatment-Resistant Hypertension Disease Background and Overview
7. Treatment-Resistant Hypertension Epidemiology and Patient Population
8. Country-Specific Patient Population of Treatment-Resistant Hypertension
9. Treatment-Resistant Hypertension Current Treatment and Medical Practices
10. Unmet Needs
11. Treatment-Resistant Hypertension Emerging Therapies
12. Treatment-Resistant Hypertension Market Outlook
13. Country-Wise Treatment-Resistant Hypertension Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Treatment-Resistant Hypertension Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Treatment-Resistant Hypertension Market Outlook 2034 https://www.delveinsight.com/report-store/treatment-resistant-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Treatment-Resistant Hypertension Pipeline Insights, DelveInsight

"Treatment-Resistant Hypertension Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Treatment-Resistant Hypertension market. A detailed picture of the Treatment-Resistant Hypertension pipeline landscape is provided, which includes the disease overview and Treatment-Resistant Hypertension treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.